SANTA ROSA, Calif.--(BUSINESS WIRE)--Keysight Technologies, Inc. (NYSE: KEYS), a leading technology company that delivers advanced design and validation solutions to ...

Fujirebio's Lumipulse® G pTau217/β-Amyloid 1-42 Plasma Ratio test has the potential to shorten the Alzheimer's disease diagnostic journey and enable earlier intervention through its accessibility and ...

Freidlin and Korn 9 critically review some of the alternative methods. Their conclusion is that these methods can be useful as secondary analyses, but they are not ready to be used in primary analysis ...